Université De Nantes

Ogd2 Pharma

Stephane Birkle

Jean-Marc Le Doussal

Mylene Dorvillius

Mickael Terme

Denis Cochonneau

Jacques Barbet

Jean-Marie Mussini

Jacques Aubry

Jean-Francois Chatal

Beatrice Clemenceau

An antibody recognizing the O-acetylated-GD2 ganglioside for the treatment of Cancer Stem Cells (CSC) cancer, a pharmaceutical composition including the antibody for treating a CSC cancer and a method for treating a CSC cancer in a patient in need thereof, the method including administering the antibody to the patient. A method for diagnosing a CSC, the use of the O-acetylated-GD2 ganglioside as a biomarker of CSC cancer, and a method for predicting the response of a subject affected with CSC cancer to a treatment with the antibody or the composition are also described.

Targeting o-acetylated gd2 ganglioside as a new therapeutic and diagnostic strategy forcancer

Targeting O-acetylated GD2 ganglioside as a new therapeutic and diagnostic strategy for cancer stem cells cancer

The monoclonal antibodies that only recognize the O-acetylated form of the GD2 ganglioside, or fragments of the antibody, for the diagnosis and the treatment of cancers in which the cells express the O-acetylated GD2, the antibody or the fragment recognizing the O-acetylated GD2 molecules expressed by the tumoral cells and not recognizing the GD2 molecules expressed at the surface of the peripheral nerves, in order to increase the specificity of the diagnosis and reduce the toxicity of the treatments. Also artificially modified antibodies advantageously used for treating and diagnosing cancers in which the cells express the O-acetylated GD2.

Use of monoclonal antibodies specific to the O-acetylated form of GD2 ganglioside for the treatment of certain cancers

Growing community of inventors

Nantes, France

Stephane Birkle